Ploidy change as a rapid mechanism of adaptation

Projektinformationen

RAPLODAPT

ID Finanzhilfevereinbarung: 340087

Abgeschlossenes Projekt

Startdatum 1 Januar 2014

Enddatum 31 Dezember 2019

Finanziert unter

• Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)

Gesamtkosten € 2 365 000,00

EU-Beitrag € 2 365 000,00

Koordiniert durch

TEL AVIV UNIVERSITY
Israel

Ziel

Fungi are particularly challenging pathogens; because they and their human hosts are eukaryotes. We will study how new traits such as drugR arise rapidly using Candida albicans, the most prevalent fungal pathogen of humans. The work explores the ground-breaking concept that alterations in genome ploidy are prevalent in drugR isolates because these genome states promote persistence and drug resistance.
We recently found that C. albicans, thought to be an “obligate diploid”, can form haploids. This represents a major paradigm shift both technologically and conceptually. We are poised to exploit this unique opportunity to reinvent genomic approaches for C. albicans by leveraging next generation sequencing, high throughput analyses and more traditional genetics. Because haploids are much less fit than heterozygous diploids, our working hypothesis is that changes in ploidy, including whole genome ploidy and aneuploidy, occur frequently under drug stress and that they make major contributions to the rapid appearance of genotypic and phenotypic diversity, in part by promoting persistence.
The objectives of this proposal are to develop next-generation technologies that leverage haploids; to characterize the conditions and genes that promote ploidy transitions, especially in the presence of drug, in vitro and in vivo and to analyze their fitness consequences. This multi-disciplinary research program will integrate = approaches at the genetic, genomic, molecular, cellular and population levels and includes computational approaches to model evolutionary processes.
The project will lead to unparalleled advances in tools for the research community, and important insights concerning how diversity arises rapidly. It will assist in efforts to design diagnostic and therapeutic strategies for preventing and treating fungal diseases, prividing insights into the rapid appearance of drug resistance in eukaryotic pathogens, and chemotherapy resistance in cancer cells.

Wissenschaftliches Gebiet

• natural sciences › biological sciences › evolutionary biology
• natural sciences › biological sciences › microbiology › mycology
• medical and health sciences › basic medicine › pharmacology and pharmacy › drug resistance
• medical and health sciences › clinical medicine › oncology
• natural sciences › biological sciences › genetics › genomes

Programm/Programme

• FP7-IDEAS-ERC - Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)

Thema/Themen

• ERC-AG-LS2 - ERC Advanced Grant - Genetics, Genomics, Bioinformatics and Systems Biology

Aufforderung zur Vorschlagseinreichung

ERC-2013-ADG
Andere Projekte für diesen Aufruf anzeigen

Finanzierungsplan

ERC-AG - ERC Advanced Grant

Gastgebende Einrichtung

TEL AVIV UNIVERSITY

Hauptforscher

Judith Berman (Prof.)

Kontakt Verwaltung

Lea Pais (Ms.)

• EU-Beitrag: € 2 331 150,50
• Adresse: RAMAT AVIV ; 69978 Tel Aviv ; Israel
• Aktivitätstyp: Higher or Secondary Education Establishments
• Gesamtkosten: Keine Daten

Begünstigte (2)

TEL AVIV UNIVERSITY

Israel

Hauptforscher

Judith Berman (Prof.)

Kontakt Verwaltung

Lea Pais (Ms.)

• EU-Beitrag: € 2 331 150,50
• Adresse: RAMAT AVIV ; 69978 Tel Aviv
• Aktivitätstyp: Higher or Secondary Education Establishments
• Gesamtkosten: Keine Daten

UNIVERSITY OF ROCHESTER

Beteiligung beendet

Vereinigte Staaten

Kontakt Verwaltung

Amanda Augustin (Ms.)

• EU-Beitrag: € 33 849,50
• Adresse: ELMWOOD AVENUE, BOX EHSC 601 ; 14642 Rochester Ny
• Aktivitätstyp: Higher or Secondary Education Establishments
• Gesamtkosten: Keine Daten